Will The Magnificent 7 Stocks Go Up This Year?
2025 was another banner year for the Magnificent Seven stocks,…
Sell
46
CASI Quote, Financials, Valuation and Earnings
Last price:
$1.10
Seasonality move
:
8.11%
Day range:
$1.02 - $1.20
52-week range:
$0.75 - $3.09
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.64x
P/B ratio:
15.65x
Volume:
116.7K
Avg. volume:
38.7K
1-year change:
-61.54%
Market cap:
$22.6M
Revenue:
$28.5M
EPS (TTM):
-$3.16
Analysts' Opinion
-
Consensus RatingCASI Pharmaceuticals, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $4.00, CASI Pharmaceuticals, Inc. has an estimated upside of 263.64% from its current price of $1.10.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $4.00 representing 100% downside risk from its current price of $1.10.
Fair Value
-
According to the consensus of 1 analyst, CASI Pharmaceuticals, Inc. has 263.64% upside to fair value with a price target of $4.00 per share.
CASI vs. S&P 500
-
Over the past 5 trading days, CASI Pharmaceuticals, Inc. has overperformed the S&P 500 by 31.43% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
CASI Pharmaceuticals, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
CASI Pharmaceuticals, Inc. revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter CASI Pharmaceuticals, Inc. reported revenues of $3.1M.
Earnings Growth
-
CASI Pharmaceuticals, Inc. earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter CASI Pharmaceuticals, Inc. reported earnings per share of -$0.68.
Enterprise value:
36.8M
EV / Invested capital:
--
Price / LTM sales:
0.64x
EV / EBIT:
--
EV / Revenue:
1.37x
PEG ratio (5yr expected):
-0.01x
EV / Free cash flow:
-1.38x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$9.6M
Return On Assets:
-112.93%
Net Income Margin (TTM):
-183.93%
Return On Equity:
-70405.41%
Return On Invested Capital:
-405.32%
Operating Margin:
-333.14%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $37.3M | $21.3M | $26.8M | $7.8M | $3.1M | |
| Gross Profit | $22M | $11.7M | $9.6M | $4M | $706K | |
| Operating Income | -$31.9M | -$37.1M | -$43.5M | -$8.1M | -$10.2M | |
| EBITDA | -$36.9M | -$32.7M | -- | -$8.1M | -- | |
| Diluted EPS | -$3.02 | -$2.22 | -$3.16 | -$0.55 | -$0.68 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $72M | $55.6M | $58.1M | $47.2M | $11.9M | |
| Total Assets | $136.3M | $127.9M | $74.2M | $65.6M | $27.3M | |
| Current Liabilities | $10M | $29.7M | $11.8M | $14.7M | $39.4M | |
| Total Liabilities | $26.8M | $44.7M | $23.8M | $49.8M | $53.1M | |
| Total Equity | $109.5M | $83.2M | $50.4M | $15.8M | -$25.7M | |
| Total Debt | $1.4M | $634K | -- | $19.1M | $18.9M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2021-12-31 | 2022-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$25.9M | -$26.8M | -$21.1M | -$7.6M | -$843K | |
| Cash From Investing | -$20.7M | -$20.7M | $31.2M | -$4.7M | $18M | |
| Cash From Financing | $47.2M | $29.6M | -$3.3M | -$1.1M | -$3.3M | |
| Free Cash Flow | -$27.4M | -$35.8M | -$26.7M | -$12.9M | -$4.3M | |
CASI
Sector
Market Cap
$22.6M
$28.1M
Price % of 52-Week High
35.6%
51.87%
Dividend Yield
0%
0%
Shareholder Yield
-0.23%
-1.59%
1-Year Price Total Return
-61.54%
-17.31%
Beta (5-Year)
0.825
0.495
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$0.89
200-day SMA
Sell
Level
$1.64
Bollinger Bands (100)
Sell
Level
1 - 2.06
Chaikin Money Flow
Sell
Level
-12.6M
20-day SMA
Buy
Level
$0.86
Relative Strength Index (RSI14)
Buy
Level
64.76
ADX Line
Buy
Level
22.82
Williams %R
Neutral
Level
-22.2222
50-day SMA
Buy
Level
$1.09
MACD (12, 26)
Sell
Level
-0.03
25-day Aroon Oscillator
Buy
Level
40
On Balance Volume
Neutral
Level
102.6M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-19.5622)
Sell
CA Score
(Annual)
Level (-4.403)
Buy
Beneish M-Score
(Annual)
Level (-2.89)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (7.1792)
Sell
Piotroski F Score
(Annual)
Level (3)
Buy
Quality Ratio Score
Level (7)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
CASI Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing innovative therapeutics and pharmaceutical products. The firm is also involved in developing innovative therapeutics addressing cancer and other unmet medical needs for the global market. The company was founded in 1991 and is headquartered in Beijing, China.
Stock Forecast FAQ
In the current month, CASI has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CASI average analyst price target in the past 3 months is $4.00.
-
Where Will CASI Pharmaceuticals, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that CASI Pharmaceuticals, Inc. share price will rise to $4.00 per share over the next 12 months.
-
What Do Analysts Say About CASI Pharmaceuticals, Inc.?
Analysts are divided on their view about CASI Pharmaceuticals, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that CASI Pharmaceuticals, Inc. is a Sell and believe this share price will drop from its current level to $4.00.
-
What Is CASI Pharmaceuticals, Inc.'s Price Target?
The price target for CASI Pharmaceuticals, Inc. over the next 1-year time period is forecast to be $4.00 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CASI A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for CASI Pharmaceuticals, Inc. is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of CASI?
You can purchase shares of CASI Pharmaceuticals, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase CASI Pharmaceuticals, Inc. shares.
-
What Is The CASI Pharmaceuticals, Inc. Share Price Today?
CASI Pharmaceuticals, Inc. was last trading at $1.10 per share. This represents the most recent stock quote for CASI Pharmaceuticals, Inc.. Yesterday, CASI Pharmaceuticals, Inc. closed at $1.10 per share.
-
How To Buy CASI Pharmaceuticals, Inc. Stock Online?
In order to purchase CASI Pharmaceuticals, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get CASI Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
CASI
Sector
P/E ratio
--
24.20x
PEG ratio
-0.01x
-0.01x
P/B ratio
15.65x
1.84x
Price / LTM sales
0.64x
1.60x
Growth Metrics
CASI
Sector
Revenue growth
-60.54%
4.51%
Earnings growth
-23.54%
10.7%
Revenue (5-year growth)
47.19%
6.45%
Earnings forecast
--
-$0.19
Profitability
CASI
Sector
Profitability FY 2024
$11.1M
$3.5M
Return on invested capital
-405.32%
-32.3%
Return on assets
-112.93%
-28.57%
Return on equity
-70405.41%
-38.09%
Earnings Date
Last Earnings Date
Nov
14
Next Earnings Date
Jan
10
Estimated Next Earnings Date
Apr
11
Balance Sheet
CASI
Sector
Total cash
$4.7M
$26M
Short term investments
$2.6M
$25.7M
Total assets
$53.7M
$76.4M
Long term debt
$18.9M
$3.2M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Planet Labs Stock Rally So Much?
Satellite imaging startup Planet Labs (NYSE:PL), after years of disappointing…
Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
100
ATGL alert for Jan 10
Alpha Technology Group Ltd. [ATGL] is up 47.05% over the past day.
Buy
71
NAIL alert for Jan 10
Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is up 18.52% over the past day.
Buy
54
LGIH alert for Jan 10
LGI Homes, Inc. [LGIH] is up 13.81% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
